PND7 Prevalence of Cystic Fibrosis Among the U. S. National Medicaid Population  by Xie, L. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A391
AD dementia. The effectiveness of this test was evaluated for diagnostic accuracy. 
Diagnostic accuracy for identifying AD by ELISA was high (pooled sensitivity, 0.772 
(95% CI 0.747–0.796); pooled specificity, 0.732 (95% CI 0.699–0.762). ConClusions: 
Reduced CSF Ab1–42 levels are of potential utility in the differential diagnosis of AD 
versus non-AD dementias and healthy controls.
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objeCtives: Cystic fibrosis (CF) prevalence according to U. S. geographic region as 
well as patient age, gender and race was examined in the U. S. Medicaid population 
for patients younger than age 45. Methods: Patients ≤ 45 years from the Medicaid 
fee-for-service (FFS) population (2008-2009) were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis 
code 277.0x. Patients were required to have continuous Medicaid FFS enrollment 
in both years and no evidence of managed care enrollment. CF prevalence was 
stratified by U. S. region, state, age group, gender and race, and was measured by 
number and percentage of patients in each category. Results: A total of 2,142 
patients were diagnosed with CF among the Medicaid FFS population under age 45 
years in 2008 and 2009. Prevalence was the highest (0.17%) for patients under age 17 
years, followed by those age 18-35 (0.14%), and 36-45 years (0.06%). However, some 
states had the highest CF prevalence in the 18-35 age range (Colorado: 0.92%; North 
Dakota: 0.50%; Kentucky: 0.54%). CF prevalence by race was also examined with 
the following results: White (0.17%), Hispanic (0.10%), Asian (0.07%), Black (0.06%) 
and Native American (0.03%). Male patients had a relatively higher prevalence 
than female patients (0.14% vs. 0.12%). The highest CF prevalence was observed in 
Colorado (0.47%), followed by Maryland (0.46%), North Dakota (0.31%), Ohio (0.28%) 
and Pennsylvania (0.27%). Patients residing in the Midwest U. S. region had the 
highest prevalence rate (0.15%), compared to the South (0.15%), Northeast (0.12%) 
and West (0.04%) regions. ConClusions: CF prevalence was the highest in patients 
age < 17 years nationwide, however, certain states showed the highest prevalence 
among patients age 18 to 35. White and male patients residing in the Midwest U. S. 
region were found to be at higher risk of a CF diagnosis.
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objeCtives: To examine claims-based relapse rates and time to relapse among mul-
tiple sclerosis (MS) patients treated with natalizumab or propensity score matched 
patients treated with platform therapy (interferon beta/glatiramer acetate) in the 
US. Methods: The Truven Health MarketScan Research Databases were used to 
identify adults with a MS (ICD-9-CM code 340) diagnosis treated with natalizumab 
or platform therapy; the first claim between January 1, 2009 and April 1, 2012 was the 
index. Patients had to have one year continuous enrollment pre- and post-index and 
remain on index therapy for 12 months. Patients were excluded if they used a non-
index therapy in the pre-index. Natalizumab and platform patients were propensity 
scored matched using nearest neighbor matching on demographic characteristics, 
selected comorbid conditions and medications, MS severity (using an adaptation 
of Kurtzke’s Functional System), pre-index relapse and pre-index expenditures. 
MS-relapse was defined as MS-related inpatient (IP) admission, IV or oral corticos-
teroid use. Cox Proportional Hazard models were used to evaluate time to relapse, 
controlling for demographic and pre-index clinical characteristics. Results: A total 
of 897 natalizumab patients met the study criteria, 882 of which were 1: 1 matched to 
882 platform therapy patients (mean age 45 years, 70% female) with a standardized 
difference < 10 on all matching measures. Compared to platform patients, natali-
zumab patients were significantly less likely to have MS-relapse post-index (26.5% 
vs. 35.5%, p< 0.001), with lower post-index rates of MS-related IP admissions (1.0% 
vs. 2.6%), IV-corticosteroid use (15.6% vs. 19.0%) and oral corticosteroid use (15.4% vs. 
23.1%) (all p< 0.001). Natalizumab patients also had 25 more relapse-free days (308 vs. 
283 days, p< 0.001). Post-index MS-relapse risk was lower for natalizumab patients 
(HR= 0.69, p< 0.001) after controlling for baseline characteristics. ConClusions: 
Natalizumab was associated with a significantly lower risk and rate of MS-relapse 
and had longer time to a MS-relapse compared to platform therapy.
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bACkgRound: The most common surgical complication associated with shunt 
placement in Hydrocephalus patients is obstruction causing shunt malfunction. 
The primary cause of obstruction is incorrect placement of the catheter tip, most 
notably in the choroid plexus. objeCtives: To investigate the clinical and eco-
nomic value of IGNS use in the accurate placement of catheters in Hydrocephalus 
patients. Methods: A search of the Embase and PubMed electronic databases was 
conducted to identify studies evaluating the accuracy, effectiveness, quality-of-life 
(QOL) and economic aspects of IGNS in patients with Hydrocephalus. No language 
restrictions were applied. Results: We conducted a meta-analysis of studies report-
ing accuracy of ventricular catheter placement in patients with hydrocephalus 
undergoing shunt placement with stereotactic IGNS versus freehand technique. The 
definition of accurate catheter placement was similar in all studies. The meta-analysis 
showed the odds of achieving an accurate catheter placement for surgeons who utilize 
IGNS was almost 6 times higher (odds ratio 5.55, 95% CI [2.84, 10.85], P< 0.00001) than 
surgeons who used freehand placement techniques. Furthermore, accurate place-
burden. Improving the control of PD motor symptoms on patients may contribute 
to prevent anxiety and HRQoL deterioration in caregivers.
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objeCtives: Gaucher disease (GD) is an inherited, rare, lysosomal storage disorder 
caused by a genetic deficiency of glucocerebrosidase. The result is the accumulation 
of the substrate, glucosylceramide, in the lysosomes of macrophage cells in the liver, 
spleen, bones, lungs, and other vital tissues. Three subtypes of Gaucher disease are 
recognized: type 1 (GD1, non-neuropathic), type 2 (GD2, acute neuropathic), and type 
3 (GD3, subacute/chronic neuropathic). Clinical manifestations of the disease are mul-
tisystemic, clinically heterogeneous and require lifelong management. Methods: 
To better understand the burden of GD, a comprehensive review of the published 
literature was conducted. MEDLINE, EMBASE, CENTRAL and “grey” literature sources 
published in English between January 1990 and February 2013 were searched for rel-
evant publications. Results: A total of 97 publications focusing on the epidemiologic, 
clinical, and socioeconomic burden of GD, treatment options and guidelines were 
summarized. The standardized incidence and prevalence of GD in the general popu-
lation varies from 0.30 to 5.80 per 100,000 and 0.33 to 1.75 per 100,000, respectively, 
and GD1 is the predominant type in most regions. The risk of mortality is highest in 
GD patients younger than age 5 years and generally increased after age 55; the life 
expectancy is lower than the general population. Common manifestations of GD such 
as anemia, thrombocytopenia, splenomegaly, hepatomegaly and bone disease lead 
to a decreased quality of life. Reported GD comorbidities include Parkinson’s disease 
and cancer. Current treatment options consist of enzyme replacement therapy (ERT, 
standard of care) and substrate reduction therapy (SRT). ERT is the standard of care, 
though unmet needs still exist, especially for GD2 and GD3. ConClusions: GD is a 
rare, chronic disease associated with significant burden to patients and caregivers. 
While ERT is an effective and well-established treatment for GD patients, several 
unmet needs exist and further research is needed in this area.
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objeCtives: Restless leg syndrome (RLS) is a condition with possibly high prevalence 
in hemodialysis (6-60% according to the literature), and a specific treatment available. 
Thus it’s important to identify it among other conditions present in this population 
that might confound diagnosis (such as peripheral vascular disease or neuropathies). 
An approach based on a self-completed screening test will be assessed in this study, 
along with an estimation of RLS prevalence in hemodialysis. Methods: Patients 
from two hemodialysis units answered a RLS screening test. Those with a positive 
screening completed the International Restless Legs Syndrome Study Group Rating 
Scale (IRLS) that assesses symptom severity. A neurophysiologist performed a clini-
cal interview to confirm the diagnosis, including a supervised administration of the 
IRLS. Results: 164 patients were recruited. Mean age was 65.7 years (range 33-87; 
Pct25-75: 55.5-77.5), 67% were male and mean time in dialysis was 64.16 months. 
Self-completed screening test identified 69 possible cases of RLS (42.07%). 44 (26.8%) 
patients had RLS symptoms according to the self-completed IRLS, and 79% of them 
were classified as having moderate to severe RLS symptoms. The clinician confirmed 
just 22 of those cases (13.4% of the total sample), with a demographic profile similar 
to the sample. The screening test had in this sample a sensitivity of 100%, specificity 
66.43% and positive predictive value 31.88%. ConClusions: This study found RLS is 
a relatively common condition in hemodialysis patients. The screening test showed 
a high sensitivity to detect RLS, but very low specificity, so the confirmation of an 
expert neurologist or neurophysiologist is neccesary.
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objeCtives: The purpose of this study was to carry out systematic review of the 
literature and meta-analysis to evaluate the diagnostic utility of cerebrospinal fluid 
(CSF) levels of the 42 amino acid form of amyloid-b (Ab1−42) as a biomarker for dif-
ferentiating Alzheimer’s disease (AD) from non-AD dementia. Methods: Design - 
Systematic literature review was used to evaluate the effectiveness of the Ab for the 
diagnosis of Alzheimer’s disease. The Scottish Intercollegiate Guidelines Network 
(SIGN) tool was used by two evaluators to evaluate independently the quality of the 
15 studies. Data sources - The literature review covered from October 27, 1946, to 
October 22, 2013, and searched eight domestic databases including Korea Med and 
international databases including Ovid-MEDLINE, EMBASE, and Cochrane Library. 
Eligibility criteria for selecting studies - Primary criteria for inclusion were valid 
studies on (i) patients with mild cognitive impairment with confirmed or suspected 
AD and non-AD dementia, and (ii) assessment of Ab1−42levels using appropriate 
comparative tests. Results: A total of 15 studies (15 diagnostic evaluation stud-
ies) were identified in which levels of CSF Ab1−42 were assessed. Meta-analysis 
was performed on nine robust studies that compared confirmed AD with healthy 
individuals (n = 1587), 10 studies that compared AD with non-AD dementias (n = 
860), and four studies that compared a-MCI (amnestic mild cognitive impairment) 
with na-MCI (non-amnestic mild cognitive impairment) subjects (n = 857). Overall, 
Ab1–42levels were reduced in CSF from AD patients versus healthy controls or non-
